[{"id":"a6fd23df-878e-47c4-a87e-35dde3ddcf83","acronym":"HS-20117","url":"https://clinicaltrials.gov/study/NCT06621563","created_at":"2025-02-26T15:00:47.900Z","updated_at":"2025-02-26T15:00:47.900Z","phase":"Phase 1","brief_title":"Phase Ib Trial of HS-20117 in Combination with Other Drugs in Advanced Solid Tumors","source_id_and_acronym":"NCT06621563 - HS-20117","lead_sponsor":"Hansoh BioMedical R\u0026D Company","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • PM1080 • risvutatug rezetecan (GSK5764227)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 780","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-10-01"},{"id":"349d0879-8996-4ca4-b3c5-eed00f81ee3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05940116","created_at":"2023-07-12T16:09:55.798Z","updated_at":"2024-07-02T16:35:43.351Z","phase":"Phase 1","brief_title":"A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05940116","lead_sponsor":"Hansoh BioMedical R\u0026D Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PM1080"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 322","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2023-07-12"}]